Takeda to reduce debt through potential sale — 4 insights

Written by Eric Oliver | September 30, 2019 | Print  |

Takeda Pharmaceutical Co. is exploring a deal to sell several of its over-the-counter and prescription drugs in emerging markets and Western Europe, The Japan Times reports.

What you should know:

1. Takeda would likely sell the drugs it acquired when it purchased Nycomed in 2011. That drug portfolio could fetch about $3 billion.

2. People familiar with the matter listed Acino International AG, Avista Capital Partners, Stada Arzneimittel AG, EMS SA and Uniao Quimica Farmaceutica Nacional as potential buyers in emerging markets.

3. Takeda is also exploring deals in Western Europe with Advent International, Apollo Global Management and Cerberus Capital Management. The potential saleable assets in this deal are valued at $1.1 billion.

4. Takeda became one of the most indebted drugmakers in the world when it acquired Shire in January.

More articles on surgery centers: 
Surgical Review Corp. awards dual accreditation to hand institute, ASC — 3 quick points
AAAHC releases 2019 quality roadmap
3 ASCs recently achieving accreditation

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.